Knowledge Management System of Hefei Institute of Physical Science,CAS
Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study | |
Fang, Y.1; Pan, H.1; Shou, J.2; Hong, W.3; Yang, X.4; Zhu, D.5; Zhou, Y.6; Lan, F.7; Rao, C.8; Chen, J.9 | |
2021-03-01 | |
发表期刊 | JOURNAL OF THORACIC ONCOLOGY |
ISSN | 1556-0864 |
关键词 | Anlotinib NSCLC anti-angiogenesis |
收录类别 | SCI |
语种 | 英语 |
WOS研究方向 | Oncology ; Respiratory System |
WOS类目 | Oncology ; Respiratory System |
WOS记录号 | WOS:000631349602067 |
出版者 | ELSEVIER SCIENCE INC |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | http://ir.hfcas.ac.cn:8080/handle/334002/121730 |
专题 | 中国科学院合肥物质科学研究院 |
作者单位 | 1.Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Med Oncol, Hangzhou, Peoples R China 2.Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Peoples R China 3.Univ Chinese Acad Sci, Canc Hosp, Hangzhou, Peoples R China 4.First Hosp Jiaxing, Jiaxing, Peoples R China 5.Jinhua Municipal Cent Hosp, Jinhua, Zhejiang, Peoples R China 6.Cent Hosp Lishui City, Lishui, Peoples R China 7.Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China 8.Univ Chinese Acad Sci, Hwa Mei Hosp, Ningbo, Peoples R China 9.Ningbo Univ, Affiliated Peoples Hosp, Ningbo, Peoples R China |
推荐引用方式 GB/T 7714 | Fang, Y.,Pan, H.,Shou, J.,et al. Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study[J]. JOURNAL OF THORACIC ONCOLOGY,2021,16. |
APA | Fang, Y..,Pan, H..,Shou, J..,Hong, W..,Yang, X..,...&Chen, J..(2021).Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study.JOURNAL OF THORACIC ONCOLOGY,16. |
MLA | Fang, Y.,et al."Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study".JOURNAL OF THORACIC ONCOLOGY 16(2021). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论